

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1616bsk

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 CA/CAPLUS records now contain indexing from 1907 to the  
present  
NEWS 4 AUG 05 New pricing for EUROPATFULL and PCTFULL effective  
August 1, 2003  
NEWS 5 AUG 13 Field Availability (/FA) field enhanced in BEILSTEIN  
NEWS 6 AUG 18 Data available for download as a PDF in RDISCLOSURE  
NEWS 7 AUG 18 Simultaneous left and right truncation added to PASCAL  
NEWS 8 AUG 18 FROSTI and KOSMET enhanced with Simultaneous Left and Right  
Truncation  
NEWS 9 AUG 18 Simultaneous left and right truncation added to ANABSTR  
NEWS 10 SEP 22 DIPPR file reloaded  
NEWS 11 SEP 25 INPADOC: Legal Status data to be reloaded  
NEWS 12 SEP 29 DISSABS now available on STN  
NEWS 13 OCT 10 PCTFULL: Two new display fields added  
NEWS 14 OCT 21 BIOSIS file reloaded and enhanced  
NEWS 15 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced  
  
NEWS EXPRESS NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:54:32 ON 21 NOV 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:54:56 ON 21 NOV 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 NOV 2003 HIGHEST RN 619253-33-7  
DICTIONARY FILE UPDATES: 20 NOV 2003 HIGHEST RN 619253-33-7

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>


=> s ta2711  
L1 0 TA2711

=> s ta 2711  
39568 TA  
83 TAS  
39650 TA  
(TA OR TAS)  
727 2711  
L2 1 TA 2711  
(TA(W)2711)

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN  
RN 86408-72-2 REGISTRY  
CN 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-  
7-(1-methylethyl)-6-sulfo-, monosodium salt, (1R,4aS,10aR)- (9CI) (CA  
INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-  
7-(1-methylethyl)-6-sulfo-, monosodium salt, [1R-  
(1.alpha.,4a.beta.,10a.alpha.)]-  
OTHER NAMES:  
CN Ecabet sodium  
CN Gastrom  
CN TA 2711  
FS STEREOSEARCH  
MF C20 H28 O5 S . Na  
LC STN Files: ADISINSIGHT, BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CAPLUS, CIN,  
DDFU, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK\*, PHAR,  
PROMT, RTECS\*, SYNTHLINE, TOXCENTER, USPATFULL  
(\*File contains numerically searchable property data)  
CRN (33159-27-2)

Absolute stereochemistry.



● Na

62 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 63 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus medline biosis embase wpix japio uspatful		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	14.74	14.95

FILE 'CAPLUS' ENTERED AT 10:55:39 ON 21 NOV 2003  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 10:55:39 ON 21 NOV 2003

FILE 'BIOSIS' ENTERED AT 10:55:39 ON 21 NOV 2003  
 COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 10:55:39 ON 21 NOV 2003  
 COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'WPIX' ENTERED AT 10:55:39 ON 21 NOV 2003  
 COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'JAPIO' ENTERED AT 10:55:39 ON 21 NOV 2003  
 COPYRIGHT (C) 2003 Japanese Patent Office (JPO)- JAPIO

FILE 'USPATFULL' ENTERED AT 10:55:39 ON 21 NOV 2003  
 CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s ecabet or ta 2711 or gastrom or 86408-72-2/rn or 33159-27-2/rn  
 'RN' IS NOT A VALID FIELD CODE  
 'RN' IS NOT A VALID FIELD CODE  
 'RN' IS NOT A VALID FIELD CODE  
 'RN' IS NOT A VALID FIELD CODE  
 'RN' IS NOT A VALID FIELD CODE

L3 345 ECABET OR TA 2711 OR GASTROM OR 86408-72-2/RN OR 33159-27-2/RN

=> s inflammatory bowel disease or ibd or colitis or crohns or crohn or ulcerative  
 colitis or behcet

L4 177577 INFLAMMATORY BOWEL DISEASE OR IBD OR COLITIS OR CROHNS OR CROHN  
 OR ULCERATIVE COLITIS OR BEHCET

=> s l3 and l4

L5 19 L3 AND L4

=> dup rem 15

PROCESSING COMPLETED FOR L5

L6 12 DUP REM L5 (7 DUPLICATES REMOVED)

=> focus

PROCESSING COMPLETED FOR L6

L7 12 FOCUS L6 1-

=> d ibib abs 1-12

L7 ANSWER 1 OF 12 WPIX COPYRIGHT 2003 THOMSON DERWENT on STN

ACCESSION NUMBER: 2003-441072 [41] WPIX

DOC. NO. CPI: C2003-116578

TITLE: Solution of **ecabet** sodium, dehydroabiatic acid, base and buffer for direct administration into intestines, to treat **inflammatory bowel disease**, **Crohn's** and **Behcet's** disease, rectal ulcers, appendicitis, enteritis, tuberculosis and **colitis**.

DERWENT CLASS: B05

INVENTOR(S): ITO, T; NARISAWA, S; SUGAYA, K

PATENT ASSIGNEE(S): (TANA) TANABE SEIYAKU CO

COUNTRY COUNT: 100

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2003028716	A1	20030410	(200341)*	JA	18
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU					
MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK					
DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ					
LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO					
RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM					
ZW					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003028716	A1	WO 2002-JP9847	20020925

PRIORITY APPLN. INFO: JP 2001-296689 20010927

AN 2003-441072 [41] WPIX

AB WO2003028716 A UPAB: 20030630

NOVELTY - Aqueous solution of **ecabet** sodium, including at least 1 w/v% (calculated on **ecabet**) sulfodehydroabiatic acid or its chloride, contains one or more pH buffer chosen from polycarboxylate and polyphosphate salts, and inorganic base. The solution has a pH of 7-8.5.

ACTIVITY - Antiinflammatory; Antiulcer; Gastrointestinal-Gen.; Antibacterial; Tuberculostatic.

No biological data given.

MECHANISM OF ACTION - None given.

USE - For treating **inflammatory bowel disease**, (claimed) including **Crohn's** disease, **Behcet's** disease, **ulcerative colitis**, hemorrhagic rectal ulcers, appendicitis, ischemic enteritis, intestinal tuberculosis, and **colitis** induced by drugs, radiation and infection.

ADVANTAGE - The solution can be administered easily, by application from a (claimed) flexible receptacle. It has fewer side effects than

previous treatments. The solution is stable and less irritating. A solution of **ecabet** sodium (2 g), methyl p-hydroxybenzoate (0.1 g), propyl p-hydroxybenzoate (0.02 g) and trisodium citrate (1 g) in water (80 ml) was adjusted to pH 7.4 with aqueous sodium hydroxide, and the solution was diluted with water to 100 ml, and 1 ml of a *Pseudomonas aeruginosa* suspension (107-108/ml) was added and mixed. The mixture was kept for 1 week at a uniform 25 deg. C; no bacteria survived.  
Dwg.0/20

L7 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:359792 CAPLUS  
DOCUMENT NUMBER: 134:348266  
TITLE: Preventive or therapeutic agent for inflammatory diseases of the intestine  
INVENTOR(S): Kono, Toru; Nomura, Masafumi  
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 23 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001034143	A1	20010517	WO 2000-JP7855	20001109
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001013025	A5	20010606	AU 2001-13025	20001109
JP 2002104962	A2	20020410	JP 2000-341840	20001109
EP 1228758	A1	20020807	EP 2000-974835	20001109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			JP 1999-321058	A 19991111
			JP 2000-225442	A 20000726
			WO 2000-JP7855	W 20001109
AB A novel preventive or therapeutic agent for inflammatory diseases of the intestine contains 12-sulfodehydroabietic acid ( <b>ecabet</b> ) as the active ingredient; this agent is suitable for oral administration or intrainestinal infusion. A patient with Crohn's disease was successfully treated by intrainestinal infusion of a suspension of <b>ecabet</b> sodium in water. Formulations are given.				
REFERENCE COUNT: 7			THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT	

L7 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1998:566538 CAPLUS  
DOCUMENT NUMBER: 129:254575  
TITLE: Protective effects of an antiulcer agent, **ecabet** sodium on colorectal carcinogenesis in rodents  
AUTHOR(S): Yarimizu, Takashi; Mitamura, Tadasu; Suzuki, Satoe; Sakamoto, Shinobu  
CORPORATE SOURCE: Third Internal Medicine, Oita Medical University, Oita, 879-55, Japan  
SOURCE: Oncology Reports (1998), 5(5), 1103-1107  
CODEN: OCRPEW; ISSN: 1021-335X

PUBLISHER: Oncology Reports  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB A new antiulcer agent, **ecabet** Na is 1 of dehydroabiatic acid derivs. prepd. from pine resin. The effects of **ecabet** Na on colorectal carcinogenesis were investigated in azoxymethane-pretreated mice with chronic **ulcerative colitis** induced by 3 repeated administration of 3% dextran sulfate Na and in 1,2-dimethylhydrazine-treated rats. Although daily treatment with **ecabet** Na did not affect the colorectal DNA-synthesizing enzyme activities and bromodeoxyuridine-immunoreactive S-phase cells, high-grade dysplasia in **ecabet** Na-treated mice was less frequent than in untreated mice. In rats, **ecabet** Na administration reduced the elevated activity of thymidylate synthetase in colorectal tumors.

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2001:294454 CAPLUS

DOCUMENT NUMBER: 135:205297

TITLE: Effect of **ecabet** sodium enema on mildly to moderately active ulcerative proctosigmoiditis: An open-label study

AUTHOR(S): Kono, Toru; Nomura, Masafumi; Kasai, Shinichi; Kohgo, Yutaka

CORPORATE SOURCE: Second Department of Surgery and Third Department of Medicine, Asahikawa Medical College, Asahikawa, Japan

SOURCE: American Journal of Gastroenterology (2001), 96(3), 793-797

CODEN: AJGAAR; ISSN: 0002-9270

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB OBJECTIVES: **Ecabet** sodium (ES), a nonabsorbable antigastric ulcer agent, has been shown to adhere to the region of an ulcer. It topically enhances gastric mucosal defensive factors such as the endogenous prostaglandins, capsaicin-sensitive sensory nerves, nitric oxide, and mucin. All of these mucosal defensive factors play an important role in maintaining the mucosal integrity of the colon and rectum. Therefore, we investigated the effect of ES in patients with mildly to moderately active ulcerative proctosigmoiditis. METHODS: In an open-label study, seven patients with mildly to moderately active **ulcerative colitis** (UC) who had an inflamed mucosa in the rectum and/or sigmoid and were resistant to 4-wk topical and systemic std. treatment were treated with an ES enema b.i.d. for 14 days. The enema consisted of ES (1 g) and tepid water (20 or 50 mL). These patients were assessed by the Clin. Activity Index, colonoscopically, and histol. before and after the ES therapy. The ES therapy was started after obtaining informed consent from the patients. RESULTS: Six of the seven patients responded to therapy and achieved clin., endoscopic, and histol. remissions. One patient was withdrawn because of increased stool frequency. All six patients who completed the study showed a significant change in the mean Clin. Activity Index score from 5.3+-.1.4 (mean +-. SD) to 0.5+-.0.8 ( $p < 0.05$ ), in the colonoscopic score from 3.0+-.0.9 to 0.8+-.0.4 ( $p < 0.05$ ), and in the histol. score from 2.7+-.0.5 to 0.5+-.0.6 ( $p < 0.05$ ), and achieved remission at the end of the study. There were no side effects attributable to the ES therapy. Five of the six patients are still in clin. remission after a median follow-up period of 5 mo. CONCLUSIONS: The ES enemas proved to be a safe and potentially useful adjuvant therapy currently available for treating patients with mildly to moderately active ulcerative proctosigmoiditis. A controlled study is necessary to confirm our results.

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2003:181547 USPATFULL  
TITLE: Tricyclic rantes receptor ligands  
INVENTOR(S): Saxena, Geeta, Vancouver, CANADA  
Tudan, Christopher R., Vancouver, CANADA  
Merzouk, Ahmed, Richmond, CANADA  
Salari, Hassan, Delta, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125380	A1	20030703
APPLICATION INFO.:	US 2001-992550	A1	20011113 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-881559, filed on 14 Jun 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO PARK, CA, 94025		
NUMBER OF CLAIMS:	38		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	1064		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In various aspects, the invention provides compounds that bind to one or more RANTES receptors for the treatment of chemokine mediated disease states, such as compounds of formula (I): ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2003:134585 USPATFULL  
TITLE: Tricyclic rantes receptor ligands  
INVENTOR(S): Saxena, Geeta, Vancouver, CANADA  
Tudan, Christopher R., Vancouver, CANADA  
Merzouk, Ahmed, Richmond, CANADA  
Salari, Hassan, Delta, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003092674	A1	20030515
APPLICATION INFO.:	US 2001-881559	A1	20010614 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO PARK, CA, 94025		
NUMBER OF CLAIMS:	38		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	3 Drawing Page(s)		
LINE COUNT:	1142		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB In various aspects, the invention provides compounds that bind to one or more RANTES receptors for the treatment of chemokine mediated disease states, such as compounds of formula (I): ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 12 USPATFULL on STN

ACCESSION NUMBER: 2003:285101 USPATFULL  
TITLE: Preparation capable of releasing drug at target site in intestine  
INVENTOR(S): Ishibashi, Takashi, Sakai, JAPAN  
Kubo, Hiroaki, Kobe, JAPAN  
Yoshino, Hiroyuki, Suita, JAPAN

PATENT ASSIGNEE(S): Mizobe, Masakazu, Takatsuki, JAPAN  
Tanabe Seiyaku Co., Ltd., Osaka, JAPAN (non-U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6638534	B1	20031028
	WO 2000006128		20000210
APPLICATION INFO.:	US 2001-744653		20010129 (9)
	WO 1999-JP3989		19990726

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1998-211678	19980728
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Spear, James M.	
LEGAL REPRESENTATIVE:	Browdy and Neimark, P.L.L.C.	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 6 Drawing Page(s)	
LINE COUNT:	1178	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A preparation capable of releasing a medicinal substance at a targeted site in the intestine, wherein the preparation dose not releases medicinal substance in endogastri at all, but can quickly release a medicinal substance when it reaches the desired site in the intestine after a certain period of time from discharge of the preparation from the stomach, and wherein a core material containing a medicinal substance is coated with a mixed film of a hydrophobic organic compound--an enteric polymer. The preparation is useful for a local therapy of inflammatory disease in the intestine such as **ulcerative colitis** or **Crohn's disease**, or an oral administrative therapy with a medicinal substance of a peptide which is apt to be decomposed chemically or enzymatically in any site except for a specific site in the intestine such as the large intestine, or with a medicinal substance whose absorption site in the intestine is limited, or the like, because a medicinal substance can be delivered selectively to a specific site in the intestine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 12 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
ACCESSION NUMBER: 2002:499956 BIOSIS  
DOCUMENT NUMBER: PREV200200499956  
TITLE: A successful treatment for cap polyposis by oral steroid administration and **ecabet** sodium enema, report of a case.  
AUTHOR(S): Ogino, Hidero [Reprint author]; et al  
CORPORATE SOURCE: Department of Internal Medicine, Toyama Prefectural Central Hospital, Toyama, Japan  
SOURCE: Stomach and Intestine (Tokyo), (April, 2002) Vol. 37, No. 5, pp. 735-740. print.  
ISSN: 0536-2180.  
DOCUMENT TYPE: Article  
LANGUAGE: Japanese  
ENTRY DATE: Entered STN: 25 Sep 2002  
Last Updated on STN: 25 Sep 2002

AB A 41-year-old woman was admitted to our hospital with the complaint of lower abdominal pain and bloody mucous stool. She had a prior diagnosis of **ulcerative colitis**, which had been unsuccessfully treated with sala-zosulphapyridine two years before admission to our hospital. Clinical examination showed severe hypoproteinemia and mild anemia. Barium enema and colonoscopy revealed multiple variously formed



polyps with redness and erosion from the rectum to the transverse colon. Biopsy specimens showed superficial erosion with elongated hyperplastic glands. These findings suggested cap polyposis. The patient responded to the combination therapy of oral steroid administration and **ecabet** sodium enema. She achieved clinical and endoscopic remission after 4 weeks.

L7 ANSWER 9 OF 12 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
ACCESSION NUMBER: 2001:456184 BIOSIS  
DOCUMENT NUMBER: PREV200100456184  
TITLE: A case of radiation **colitis** improved by enema therapy with **ecabet** sodium.  
AUTHOR(S): Matsumoto, M. [Reprint author]; Maruta, M. [Reprint author]; Maeda, K. [Reprint author]; Utsumi, T. [Reprint author]; Sato, Y. [Reprint author]; Takizawa, K. [Reprint author]; Masumori, K. [Reprint author]; Matsuoka, H. [Reprint author]  
CORPORATE SOURCE: Department of Surgery, Fujita Health University School of Medicine, Toyoake, Aichi, Japan  
SOURCE: Journal of the Japan Society of Coloproctology, (July, 2001) Vol. 54, No. 7, pp. 489-492. print.  
CODEN: NDKGAU. ISSN: 0047-1801.  
DOCUMENT TYPE: Article  
LANGUAGE: Japanese  
ENTRY DATE: Entered STN: 26 Sep 2001  
Last Updated on STN: 22 Feb 2002

AB Radiation therapy is one choice for malignant disease of the lower abdomen. However, radiation sometimes induces radiation **colitis** as a severe side effect. Radiation **colitis** sometimes causes severe bleeding, and it is often difficult to treat, A 66-year-old man received radiation therapy (external radiation with 65.2 Gy) for carcinoma of the bladder. Bleeding in the rectum occurred approximately 15 months after irradiation. Severe bleeding and anemia could not be controlled by Salazosulfapyridine(R) and steroid enemas, and frequent blood transfusion was needed. Therefore, we gave **ecabet** sodium enemas to this patient, twice every day, for four weeks. Bleeding and anemia could be controlled by this treatment. It is suggested that **ecabet** sodium enema can be an available treatment for radiation **colitis**

L7 ANSWER 10 OF 12 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
ACCESSION NUMBER: 2000:258450 BIOSIS  
DOCUMENT NUMBER: PREV200000258450  
TITLE: Evaluation of the use of **ecabet** sodium enema in patient with refractory **ulcerative colitis**: Preliminary report.  
AUTHOR(S): Nomura, Masafumi [Reprint author]; Kono, Toru; Kasai, Shinichi; Ashida, Toshifumi; Kohgo, Yutaka  
CORPORATE SOURCE: Teine-Keijinkai Hosp, Sapporo, Japan  
SOURCE: Gastroenterology, (April, 2000) Vol. 118, No. 4 Suppl. 2 Part 1, pp. AGA A585. print.  
Meeting Info.: 101st Annual Meeting of the American Gastroenterological Association and the Digestive Disease Week. San Diego, California, USA. May 21-24, 2000. American Gastroenterological Association.  
CODEN: GASTAB. ISSN: 0016-5085.  
DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 21 Jun 2000  
Last Updated on STN: 5 Jan 2002


L7 ANSWER 11 OF 12 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
ACCESSION NUMBER: 2002:207781 BIOSIS

DOCUMENT NUMBER: PREV200200207781  
TITLE: Alternative therapeutic strategies for intractable  
ulcerative colitis.  
AUTHOR(S): Makiyama, Kazuya [Reprint author]  
CORPORATE SOURCE: Department of Endoscopy, Nagasaki University School of  
Medicine, Nagasaki, Japan  
SOURCE: Japanese Journal of Gastroenterology, (January, 2002) Vol.  
99, No. 1, pp. 1-14. print.  
ISSN: 0446-6586.  
DOCUMENT TYPE: Article  
LANGUAGE: Japanese  
ENTRY DATE: Entered STN: 20 Mar 2002  
Last Updated on STN: 20 Mar 2002

L7 ANSWER 12 OF 12 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
ACCESSION NUMBER: 2000:257217 BIOSIS  
DOCUMENT NUMBER: PREV200000257217  
TITLE: Protective effect of **ecabet** sodium solution enema  
in experimental colitis models in rats.  
AUTHOR(S): Kono, Toru [Reprint author]; Ohara, Kei; Nomura, Masafumi;  
Yoneda, Masashi; Ashida, Toshifumi; Kohgo, Yutaka; Kasai,  
Shinichi  
CORPORATE SOURCE: Asahikawa Med Coll, Asahikawa, Tochigi, Japan  
SOURCE: Gastroenterology, (April, 2000) Vol. 118, No. 4 Suppl. 2  
Part 1, pp. AGA A582-AGA A583. print.  
Meeting Info.: 101st Annual Meeting of the American  
Gastroenterological Association and the Digestive Disease  
Week. San Diego, California, USA. May 21-24, 2000. American  
Gastroenterological Association.  
CODEN: GASTAB. ISSN: 0016-5085.  
DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 21 Jun 2000  
Last Updated on STN: 5 Jan 2002

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN  
 RN 86408-72-2 REGISTRY  
 CN 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-, monosodium salt, (1R,4aS,10aR)-(9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-6-sulfo-, monosodium salt, [1R-(1.alpha.,4a.beta.,10a.alpha.)]-  
 OTHER NAMES:  
 CN Ecabet sodium  
 CN Gastrom  
 CN TA 2711  
 FS STEREOSEARCH  
 MF C20 H28 O5 S . Na  
 LC STN Files: ADISINSIGHT, BEILSTEIN\*, BIOSIS, BIOTECHNO, CA, CAPLUS, CIN, DDFU, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK\*, PHAR, PROMT, RTECS\*, SYNTHLINE, TOXCENTER, USPATFULL  
 (\*File contains numerically searchable property data)  
 CRN (33159-27-2)

Absolute stereochemistry.



● Na

62 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 63 REFERENCES IN FILE CAPLUS (1907 TO DATE)